Prostate cancer tx Xtandi·Zytiga, 5% pt copayment applied

By Lee, Tak-Sun | translator Kim, Jung-Ju

23.10.25 15:54:38

가나다라 0

Reduced from 5.84 million won to 660,000 won per patient per year

Xtandi's upper limit is lowered due to the expansion of its scope of use

Zytiga was adjusted ex officio by being registered as a generic by Hanmi Pharmaceutical

Mandatory coverage is applied to some treatments for prostate cancer treatments Xtandi soft capsule 40mg and Zytiga, which is expected to reduce the financial burden on patients. This is a measure of fairness as Erleada is subject to mandatory benefit as it was previously listed.

The HIRA announced that it will revise the anticancer drug reimbursement standards including this information starting in November. Xtandi's pt copayment will be lowered from 30% to 5% due to expanded coverage for ADT combination therapy (first-line palliative treatment) for metastatic hormone-sensitive prostate cancer. Zytiga also lowers the pt copayment of prednisolone + ADT combination therapy (first-line, palliative treatm

Lee, Tak-Sun(hooggasi2@dailypharm.com)

If you want to see the full article, please JOIN US (click)